Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants.

Autor: Belik M; Institute of Biomedicine, University of Turku, Turku, Finland. milja.j.belik@utu.fi., Jalkanen P; Institute of Biomedicine, University of Turku, Turku, Finland., Lundberg R; Institute of Biomedicine, University of Turku, Turku, Finland., Reinholm A; Institute of Biomedicine, University of Turku, Turku, Finland., Laine L; Finnish Institute for Health and Welfare, Helsinki, Finland., Väisänen E; Institute of Biomedicine, University of Turku, Turku, Finland.; Finnish Institute for Health and Welfare, Helsinki, Finland., Skön M; Finnish Institute for Health and Welfare, Helsinki, Finland., Tähtinen PA; Department of Paediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, Finland., Ivaska L; Department of Paediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, Finland., Pakkanen SH; Department of Infectious Diseases, Meilahti Vaccination Research Center, MeVac, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Häkkinen HK; Department of Infectious Diseases, Meilahti Vaccination Research Center, MeVac, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Ortamo E; Department of Infectious Diseases, Meilahti Vaccination Research Center, MeVac, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Pasternack A; Department of Physiology, University of Helsinki, Helsinki, Finland., Ritvos MA; Department of Physiology, University of Helsinki, Helsinki, Finland., Naves RA; Department of Physiology, University of Helsinki, Helsinki, Finland., Miettinen S; Department of Virology, University of Helsinki and HUSLAB, Helsinki, Finland., Sironen T; Department of Virology, University of Helsinki and HUSLAB, Helsinki, Finland.; Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland., Vapalahti O; Department of Virology, University of Helsinki and HUSLAB, Helsinki, Finland.; Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland., Ritvos O; Department of Physiology, University of Helsinki, Helsinki, Finland., Österlund P; Finnish Institute for Health and Welfare, Helsinki, Finland., Kantele A; Department of Infectious Diseases, Meilahti Vaccination Research Center, MeVac, Helsinki University Hospital and University of Helsinki, Helsinki, Finland., Lempainen J; Institute of Biomedicine, University of Turku, Turku, Finland.; Department of Paediatrics and Adolescent Medicine, Turku University Hospital and University of Turku, Turku, Finland.; Clinical Microbiology, Turku University Hospital, Turku, Finland., Kakkola L; Institute of Biomedicine, University of Turku, Turku, Finland., Kolehmainen P; Institute of Biomedicine, University of Turku, Turku, Finland., Julkunen I; Institute of Biomedicine, University of Turku, Turku, Finland. ilkka.julkunen@utu.fi.; Clinical Microbiology, Turku University Hospital, Turku, Finland. ilkka.julkunen@utu.fi.
Jazyk: angličtina
Zdroj: Nature communications [Nat Commun] 2022 May 05; Vol. 13 (1), pp. 2476. Date of Electronic Publication: 2022 May 05.
DOI: 10.1038/s41467-022-30162-5
Abstrakt: Two COVID-19 mRNA (of BNT162b2, mRNA-1273) and two adenovirus vector vaccines (ChAdOx1 and Janssen) are licensed in Europe, but optimization of regime and dosing is still ongoing. Here we show in health care workers (n = 328) that two doses of BNT162b2, mRNA-1273, or a combination of ChAdOx1 adenovirus vector and mRNA vaccines administrated with a long 12-week dose interval induce equally high levels of anti-SARS-CoV-2 spike antibodies and neutralizing antibodies against D614 and Delta variant. By contrast, two doses of BNT162b2 with a short 3-week interval induce 2-3-fold lower titers of neutralizing antibodies than those from the 12-week interval, yet a third BNT162b2 or mRNA-1273 booster dose increases the antibody levels 4-fold compared to the levels after the second dose, as well as induces neutralizing antibody against Omicron BA.1 variant. Our data thus indicates that a third COVID-19 mRNA vaccine may induce cross-protective neutralizing antibodies against multiple variants.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: